Pharmarack now projects GLP-1 agonists to grow 111% in 2026, and anti-infectives 7.3% (Pharmarack, July 2026).
In this blog:
I hear a version of this from many pharma sales operations heads. Each division wants its own plan. Chronic wants one thing, acute another, the launch team a third. So each gets its own spreadsheet. Then a common rule changes, and every sheet needs the same fix.
Divisions should differ. Their markets grow at different speeds, and their MRs do different work. Different plans are fine. Payouts go wrong when they run on different files. Habits differ, and no common record exists.
Ask your sales ops head this week: if one rule changed tomorrow, how many files need editing?
Your data is in safe hands. Check out our Privacy policy for more info
Pharmarack now projects GLP-1 agonists to grow 111% in 2026, and anti-infectives 7.3% (Pharmarack, July 2026).
In this blog:
I hear a version of this from many pharma sales operations heads. Each division wants its own plan. Chronic wants one thing, acute another, the launch team a third. So each gets its own spreadsheet. Then a common rule changes, and every sheet needs the same fix.
Divisions should differ. Their markets grow at different speeds, and their MRs do different work. Different plans are fine. Payouts go wrong when they run on different files. Habits differ, and no common record exists.
Ask your sales ops head this week: if one rule changed tomorrow, how many files need editing?
Indian pharma companies split their field force by therapy. Each division sells a different basket to different doctors.
Those baskets grow at very different speeds. The Indian pharma market closed 2025 at ₹2,40,672 crore, up 8.1%. In July 2026, Pharmarack raised its 2026 forecast to 11.3%. Within that, it projects cardiac at 14% and anti-diabetics at 13.2%. GLP-1 agonists are projected at 111%, while anti-infectives sit at 7.3%.
Source: Pharmarack, as reported by ANI in The Tribune, January 2026; Pharmarack revised 2026 outlook, as reported by BioSpectrum, July 2026
The forecast itself moved too. In January, Pharmarack expected 7.8% to 8.1% growth for 2026. By July, it expected 11.3%. Targets set on January's outlook were stale by mid-year in several divisions.
So each division needs its own targets, focus brands and weights. That part is right. Trouble starts when each plan also gets its own file and process.
Then the work multiplies. Ten divisions means ten calculations, ten validations and ten sets of approvals. A shared rule, like a new joiner's proration, gets edited ten times. One missed edit means one division pays differently for the same event.
Different division plans are right. Separate files for each are the problem.
A good multi-division setup splits the plan into two layers. One layer belongs to each division. The other is shared by all.
| Plan element | Division-specific or shared | Why |
|---|---|---|
| Focus brands and weights | Division-specific | Each division sells a different basket |
| Targets | Division-specific | Therapy areas grow at different speeds |
| Gates (call average, coverage) | Division-specific levels, shared logic | Specialist and GP divisions call differently |
| Slab structure | Shared shape, division-specific values | MRs who move divisions read one familiar format |
| Proration for joiners, transfers and exits | Shared | The same event should pay the same way |
| Data cut-off and payout calendar | Shared | Finance closes one period for every division |
| Exception approvals | Shared | One approval path, one record |
| Query path | Shared | MRs and managers raise queries the same way |
The split follows one test. If a rule reflects the market, let it differ. If a rule reflects fairness or control, keep it common.
Let markets shape the division layer. Keep fairness and control in the shared layer.
Transfers need a rule too. An MR who moves divisions mid-month earns under two plans. Write the split into the shared layer. The method is in retrospective incentive calculation. The dates belong on the incentive time map.
Here is how one move reads. An MR moves from the acute division to chronic on 16 October.
| Part of month | Plan | Prorated target | Sales | Achievement |
|---|---|---|---|---|
| 1 to 15 October | Acute | ₹1.94 lakh (15/31 of ₹4 lakh) | ₹2.1 lakh | 108% |
| 16 to 31 October | Chronic | ₹2.58 lakh (16/31 of ₹5 lakh) | ₹2.3 lakh | 89% |
Illustrative numbers, not client data.
Each part pays on its own plan's slabs and gates. The MR sees both parts on one statement. The rule is written once, and applies to every move.

One template, dated variants and one run keep many plans manageable.
Kennect is an AI-led sales performance and incentive compensation management platform. It runs incentives for more than 60,000 MRs in India. One rule engine runs every division's plan.
KAI in practice. A sales head asks why the chronic division underperformed in one region. KAI Insights shows the brands and HQs behind the gap. An MR asks why his October payout split in two. KAI Exceptions explains both parts and logs the query.
One engine lets each division keep its plan without its own process.
FY 2027-28 plans get designed from January to March 2027. That is when the shared layer is easiest to set.
Start with a count. List every division plan and every file it lives in. Mark the rules that appear in all of them. Those rules become the shared layer. Each division then keeps only what its market needs. Leave room for a mid-year target revision. 2026 showed how far a forecast can move.
For the wider plan design, see our pharma sales incentive plan guide.
Set the shared layer first, and build the division plans on top of it.
Ten divisions, ten spreadsheets?
See every division plan run on one engine.
See pharma incentives on Kennect




Yes, for the parts that reflect its market: focus brands, weights, targets and gate levels. Rules about fairness and control should stay common across divisions. That includes proration, data cut-off, exception approvals and the query path.
Split the month at the move date. Read sales before the move against the old plan, and after it against the new one. Prorate targets by days. Write that split into the shared rules before the period opens.
Run every division on the same data, cut-off and engine. Then compare payout against achievement on one view. Add incentive cost as a share of sales. What-if modeling lets finance compare a plan's cost before launch.
A shared rule lives in many copies, so one change needs many identical edits. A missed edit makes one division pay differently for the same event. Keeping shared rules in one place removes that risk.
Before division plans are drafted for the new year. For FY 2027-28, that means January to March 2027. Setting the shared layer first lets each division plan start from a common template.